SpliceCore® Discovery Pipeline

About Envisagenics

Envisagenics is a private, AI-driven biotech founded in 2014, specializing in the discovery of RNA splicing-based drug targets. Its core technology, the SpliceCore® platform, analyzes complex transcriptomic data to identify novel, prevalent, and disease-specific splicing events with high therapeutic potential, primarily in immuno-oncology and neurodegeneration. The company has secured Series B financing and established key research collaborations with major pharmaceutical partners like Bristol Myers Squibb, Biogen, and Johnson & Johnson. Envisagenics operates as a pre-clinical, pre-revenue therapeutics developer, advancing its pipeline through strategic partnerships.

Therapeutic Areas